JGL Company profile

WE CONTINUOUSLY STRIVE TO ADAPT TO NEEDS OF THE
SOCIETY AND TO IMPROVE HEALTH IN GENERAL
As witnesses and participants of the fast changes
within the global community, but also as a multinational pharmaceutical company, at JGL we continuously strive to adapt to needs of the society and to
improve health in general. We go to great lengths
to improve our work processes and we believe that
with an experienced and motivated team, by investing our efforts, building partnerships with relevant
companies throughout the world and providing the
highest quality of services and business standards
harmonised with European practices, we can be
competitive on the local, regional and global market.
By building relationships with our customers and
partners based on mutual trust, respect and openness, and a continual investment into the development of new products and education of our employees, we have succeeded in becoming a successful
and profitable company. We proudly stress that we
are present on approximately forty markets, focused
on further globalization of business based on the
principles of sustainable development, which
implies economic growth, alongside environmental balance and social progress.
Also, we are dedicated to helping our employees achieve and maintain a balance between
work and private life, which is a prerequisite of
general satisfaction and improving quality of life
of individuals. Without their commitment and
excellence, their enthusiasm and selfless giving,
it would not have been possible to achieve the
results we present on this pages.
All our active projects, as well as those yet to be
launched, represent a very important step towards
establishing a modern and developed business
system with the aim of increasing the company’s
competitiveness and they lead to achieving the
ambitious objectives we have established.
T h e n A n d N ow
IN 2010 JGL WAS AWARDED THE STATUS OF SUPERBRANDS CROATIA
The same year saw the registration of the first product in the medicines category – Carbo Medicinalis tablets, while the “Sunce
moje malo“ product range was the first in the cosmetics segment.
The beginning of JGL’s market operation was characterized by
JADRAN GALENSKI LABORATORIJ d.d. (JGL d.d.) was es- the entrepreneurial spirit of its founders who used the niche
tablished in 1991 as the first and only privately-held pharma- strategy with several pharmacologically essential drugs of small
ceutical joint-stock company in Croatia. It developed from a production series, which allowed the company to quickly encentral laboratory for manufacturing and controlling magis- ter the international markets of Central, South-east and Eastern
tral and galenic preparations of the JADRAN Rijeka Pharmacy. Europe and the Commonwealth of Independent States (CIS).
Transformation from a central laboratory into a strong regional and,
in certain business segments, international pharmaceutical company
has been achieved thanks only to organic growth followed by continual investment in the education of employees, early recognition of
market opportunities, following trends and commitment to quality,
but also the overall systemic strategic thinking.
The basic activities include research and development, registration,
manufacture, marketing and sale of drugs, dietetic and medicinal
products and dermocosmetics. The company’s production plants and
laboratories are located in Rijeka, on Svilno and Pulac locations.
By timely integration, the company’s business operations have been
diversified through the foundation of the Pablo health institution
consisting of 36 pharmacies throughout Croatia.
Today JGL’s corporate portfolio includes 100 brands, 540 products
and 1100 product variations. Although the primary therapeutic focus
is on treating the senses - production of sterile eyes and nose drops - Today JGL is present in some 40 markets, and it wishes to make its key brands
the company also manufactures drugs for the cardiovascular system, - Aqua Maris, Meralys, Lactogyn, Normia, Prolife, Vitalia, Holyplant
blood and hematopoietic organs, as well as drugs for the digestive sys- and Dramina - international and introduce them to new global markets.
tem and the exchange of substances in almost all technological forms.
Teamwork
In order to achieve a common goal, we cooperate on all levels of the
company. We share information and resources, communicate in an
open, direct and honest manner, with mutual respect, and we build
long-term partnership relationships.
Excellence
We have clear and high goals, as well as quality and performance related
standards. We are bold and passionate in achieving results. We encourage
ourselves and others to participate in continuous learning and development, to assume responsibility and take initiative.
Closeness in customer relations
The first and foremost focus in our decision-making process are our
customers, since their needs and expectations exceed the sole need
for the product. We want to be the customer’s partner and their first
solution in business.
Globalization of business operations
We tend to achieve an even higher level of recognition on foreign
markets. We estimate that the Aqua Maris line of products has the largest potential in this respect, since it has already proved to be an exceptionally successful and competitive brand.
Closeness
We recognize the needs of our partners and meet them. We work for
our mutual benefit, by taking diversity into account. We are simple, open
and friendly in our communication.
Operational efficiency
We want to keep growing, but we must do so in a way which does not
pose a threat to our profit and efficiency. We must find a good cost to
investment balance, focus on small-scale but sustainable, long-term growth.
Technological devotion
We want to use our strengths and knowledge to focus on the areas in
which we can stand out and achieve competitive edge. This primarily means development and production of sterile pharmaceutical forms.
C o rpo rat e grow th
With an average and continuous annual growth of 25% JGL is
the fastest growing Croatian pharmaceutical company. By implementing the development strategy for new products and expanding to new markets, the overall revenue of the JGL Group
has risen from EUR 200,000 in 1991 to EUR 107,000,000 in 2012.
According to the analysis of 200 biggest global generic pharmaceutical companies carried out by Plimsoll, British institute
for industrial research and analysis based on 4-year financial
statements, JGL is 140th in terms of total revenue and 89th
according to the profitability indicator.
P O RT FO L I O
Visible difference
The production programmes of JGL are for the best part a result of
our development. They have been developed by a team of experts
in pharmaceutical technology, control and testing of drugs in cooperation with many experts. JGL manufactures series of essential drugs
of narrow pharmacological groups, generic drugs, drugs based on
valuable natural raw materials, dietary products and dermatology and cosmetics products for children and adults. The company’s portfolio consists
of more than 500 products developed and manufactured as sterile solutions, solid oral forms, semi-solid forms and solutions divided into three
programme groups - Prescription, OTC and Aqua Maris.
PR E S C R IP TI O N P RO GR AMME
OVERVIEW OF LAUNCHING OF PRESCRIPTION PROGRAMME BRANDS
A generic drug is a pharmaceutical product identical or bioequiv- er a dozen key groups according to the ATK classification. With
alent to the original drug in terms of dosage, safety, route of ad- its world wide strategy based on business-to-business partministration, quality, form, type of administration and indications. nership, the ophthalmological group of products, particularly
stands out within the programme.
Once the patent protection of the original drug expires, every
drug producer can manufacture it as a replacement product The eye drop programme represents the company’s strategic
for the original drug, provided that it complies with the rules of objective and these products will be placed on new markets.
good manufacturing practice and good clinical practice. From According to the sales results, the leading ATK groups are C, B,
its first drug registered in 1991 until today, JGL has registered A and S. These four groups make up for over 75% of total sales
of JGL’s prescription programme.
approximately one hundred new medications.
The goal of the production process is to meet various market demands in regards to technological forms and therapeutic
groups. This is why JGL’s drugs in the form of tablets, capsules,
granulates, solutions, sterile drops, ointments and creams cov-
Thanks to its own technological innovation and successful production validation process, the company has manufactured a
drug that has been successfully launched on several European
markets through its licence partner, the Swiss company Siegfried.
NO N-P R E S C R I P T I O N P RO G R AM M E
OVERVIEW OF LAUNCHING OF NON-PRESCRIPTION PROGRAMME BRANDS
NO FACTORY IN THE WORLD WORKS IN SUCH A PRECISE AND
PERFECT MANNER AS A FACTORY INSIDE A SMALL PLANT...
Dr. Schierbaum
The trend of working on improving the quality of life and ad- as prescription drugs, to guarantee the effectiveness and applicavancing health issues are fundamental reasons for permanent tion safety to patients.
development of this part of the company portfolio.
Non-prescription preparations are used for the prevention of
disease, but are also a part of the overall approach to treatment.
During the process of production, registration and quality control
for patient safety, OTC drugs are subject to the same procedure
The portfolio covers a wide range of products from the categories of OTC drugs, probiotics, food supplements, special-purpose cosmetics and cosmetics that are not medications, but can
greatly contribute to preservation of health.
OVERVIEW OF LAUNCHING OF JGL PROBIOTICS
Probiotic brands like Prolife, Lactogyn i Normia have a special place in terms of self-treatment and provide both professionals in the field and end users with innovative probiotic
solutions, a result of the latest scientific accomplishments.
Within the group of OTC drugs, the Dramina brand for
In the category of dietary supplements, the strongest brand prevention of motion sickness plays an important role, as
is Vitalia, a line of dietetic products based on well chosen well as Pantexol, a line designed for the care and protecand professionally formed herbal and vitamin constituents, tion of sensitive and damaged skin. In accordance with
aimed at providing the consumer with preventive protection JGL’s focus on the ophthalmics portfolio, within the profrom the consequences of the modern lifestyle and ageing. gramme we develop Vizol S products for the segment.
OVERVIEW OF LAUNCHING THE VITALIA BRAND PRODUCTS
AQ UA MAR I S P ROGRA MME
AQUA MARIS WAS AWARDED THE SUPERBRANDS CROATIA STATUS IN 2008, AND TWO YEARS LATER
IT RECEIVED THE BEST BUY AWARD IN THE “NOSE SPRAY” CATEGORY
The idea of using seawater for treatment, especially diseases of the respiratory tract, has been present since the ancient times. Building on the
long tradition of thalassotherapy, the practice of healing with the help
of the sea, present on the Adriatic coast and the spirit of the Mediterranean, since 1999 JGL has offered improved therapeutic Adriatic seawater resources in the form of the Aqua Maris product line.
Aqua Maris products are produced in accordance with a strictly controlled pharmaceutical quality, as confirmed by numerous clinical
studies and positive opinions from specialists in ETN and paediatrics.
Since they are absorbed by the human body, including the most sensitive and delicate group, infants and children, their purity and mild
effect are of paramount importance.
AQ UA MAR I S PRO G RA MM E
OVERVIEW OF LAUNCHING OF PRODUCTS FROM THE AQUA MARIS AND MERALYS RANGE
THE MAGNIFICENCE OF THE SEA
...
Sitting on a bench, protected from the wind,
Although my mouth is open, I cannot say a single word
Faced with the magnificence of the sea,
And the azure murmur of eternity.
Dragutin Tadijanović
Dubrovnik (Park Gradac), 27 September 1954, Monday afternoon
100% NATURAL PROTECTION
AGAINST ALLERGIES
300 microbiological examinations a year
3300 analyses of the ionic composition
16000 pH examinations
16000 osmolality examinations
Over the years JGL has enriched its offer by introducing a
product range for ear, nose and and throat care and treatment. Thanks to this brand, the company is the second
manufacturer of saline solutions for nasal care in the world.
JGL implemented the knowledge and seawater processing into its innovative product, Meralys, in which it combines a
technology, as well its experience gained through broad clin reliable drug, xylometazoline, and the healing effects of seacal research and cooperation with the biggest clinical centres water. Meralys has a quick and lasting effect.
PROD U CTIO N
The production capacities within JGL are constantly modernized and expanded as part of continuous investments.
Targeted investment in modern technological processes
is the basis for creating an efficient quality product. Since
2002, when the sterile solution production plant and the
new raw material storage facility were opened, production
capacities have been expanded with the solid oral forms
plant, quality control and analytical laboratory, microbiological laboratory and a modern plant for semi-solid pharmaceutical forms, conforming to EU GMP standards.
Research and development activities follow the development of
JGL’s production technology and adapt to it with the aim of achieving
optimum transfer of formulas from laboratory to production conditions. In order to retain ideal adaptability to needs of the market,
over the past years company experts have networked high-quality
knowledge and competence with selected partners and participated
in an increased number of co-development, co-marketing, liceing
and contractual production projects for partners in the highly-regulated Western European and Northern American markets. JGL has
been recognized as an attractive partner by many global companies.
G L O B A LI SATI O N
AWARD OF THE CROATIAN EXPORTERS ASSOCIATION FOR THE BEST EXPORTER IN RUSSIA IN 2009 AND 2010
Globalisation of business operations and key brands are It was continued with the company opening to the RusJGL’s strategic priority. The globalisation process be- sian market, and than the other CIS markets, such as
gan in early 1990s with territorial expansion to SEE markets. Ukraine and Kazakhstan, where JGL maintains its position.
Today the company exports or is planning to export its products to some
30 markets. Thanks to contractual production and partnerships with well
known pharmaceutical companies from the EU, JGL is present in another
dozen companies around the world. By the year 2018 an introduction to 20
new markets is planned, focusing on the large, fast-growing markets such
as South America, the Middle East, Africa and Far East. It is estimated that
the Aqua Maris and Meralys product ranges have the biggest potential for
global breakthrough, as well as the brand generics and OTC preparations
ophthalmologic portfolio, which will have the opportunity for international
expansion through B2B cooperation in the area of development, production and marketing. Our forecasts indicate that within three years JGL could
be present on more than 50 markets.
Q UA LI T Y
At JGL, we are dedicated to improving the quality of life by
taking care of your health. Hence, ensuring a strict quality
control process in all stages of the production is the company’s key priority.
Only this philosophy leads JGL to greatness. Along with
the basic production processes, the unique and integrated
quality system at JGL also encompasses all other processes,
essential for company development and sustainable growth.
We use the latest techniques and methods in analyses to ensure reli- ment is the key element of the company’s management and the guarable results of conducted tests. The principle of continuous improve- antee of sustainability, development and success of JGL.
E M P LOYE E S
THE COMPANY WAS AWARDED THE EMPLOYER
PARTNER CERTIFICATE FOR EXCELLENT HUMAN
RESOURCE MANAGEMENT IN 2011
JGL’s goal is to develop a culture focused on partners and customers, as well
as on excellent results. By working hard and developing innovative procedures
and products, as well as building business relations based on trust and genuine
care, JGL wishes to be a part of the solution of the business challenges of its
customers and partners.
The company is a place where teamwork, innovation and proactive lateral services are present on all levels. We operate in accordance with the highest quality standards and focus on long-term and close relationships with our customers, partners and the JGL family.
As of 31 December 2012, the average number of employees was 602, of
which 340 work in Croatia, 161 in Russia, 55 in Ukraine, 31 in Kazakhstan
and 15 in the SEE region. The average age of employees is 38, which
makes for a highly dynamic, modern and entrepreneurial company environment.
Continuous learning and improving efficacy is crucial for
JGL’s success, which is why we give all our employees a
chance to grow and advance. In addition to professional work-
shops, we also offer programmes focusing on development of
key competences of our employees. We nurture an environment of continuous improvement of efficacy.
We have been attracting and trying to keep the best for years. In this
sense, good personal relations, respect and compassion are the basic
elements of successful work and one of the most important elements
of the employee’s satisfaction.
FU TU RE
By purchasing another 78,000 square meters of facilities on
the Svilno location, JGL intends to bring all its locations under a common one. The Svilno 2 complex (Pharma valley),
will present an extension of the existing production location
in Svilno 1 and will bring to the company significant development, production and storage capacities that will also help
ensure key resources in the vision of sustainable, planned and
profitable horizontal growth over the period of ten years.
Considering that the company is focused on the development and production of drugs for the senses, additional capacities and the technical
equipment of new plants for sterile solutions and the new aerosols
and equipping of solutions plant will certainly help JGL’s key brands to
take a further step forward onto the global health market. The project
includes major reconstruction, conversion and upgrade of the existing
facilities, as well as construction of new ones, and will be realized in
three phases, according to the established plan. JGL’s new production
and technological investment will certainly change the skyline of Rijeka
and serve as an impetus for employment and economic development.
SEN SE OF RESPON S IBILIT Y
AWARD OF THE THE CROATIAN CHAMBER OF ECONOMY AND THE CROATIAN BUSINESS
COUNCIL FOR RESPONSIBILITY AND THE APPLICATION OF THE PRINCIPLE OF
CORPORATE SUSTAINABILITY
As a witness and participant of the fast changes within the global com- mu- into the local community from the very beginning and it is often involved
nity, JGL continuously strives to adapt to needs of the society and to im- in projects and initiatives contributing to the development of social surprove health in general. JGL has recognized the importance of investing roundings, to benefit the entire community.
JGL strives to continually improve and advance the working
and environmental conditions, all the while reducing the effects on the environment, raising the awareness of diversity
and inclusion and supporting the highest ethical standards
of manufacturing quality products. Through its active participation in humanitarian and ecological activities in the local
community and elsewhere, JGL gives back to the community.
In 2011 the company improved the existing relationships based on mutual trust through a
visually refreshing corporate identity and its official slogan which says that it keeps its customers, partners and family as precious as a drop of water.
NATIONAL OFFICES
REGIONAL OFFICES
WORLDWIDE OFFICES
JGL d. d.
Pulac 4a
51000 Rijeka
t: +385 51 546 024
jgl@jgl.hr
JGL Slovenia
JGL Russia
Litostrojska cesta 46a
1000 Ljubljana
t: +386 1 5372 730
jgl-lj@j-gl.si
Lomonosovsky avenue 38
119330 Moskva
t: +7 495 970 18 82
jadran@jgl.ru
JGL Zagreb
JGL Serbia
JGL Ukraine
Šarengradska 4a
10000 Zagreb
t: +385 1 36 57 000
jgl@jgl.hr
Ul. Mirijevski Bulevar 37a
11000 Beograd
t: +381 11 277 16 31
jgl@jgl.rs
28 Institutska str. block E
01021 Kijev
t: +380 44 377 54 17
jadran@jgl.com.ua
JGL Osijek
JGL Bosnia-Herzegovina
JGL Kazakhstan
Sutlanska 5
31000 Osijek
t: +385 31 297 657
jgl@jgl.hr
Igmanska bb
71340 Vogošća Sarajevo
t: +387 33 580 920
jadran@epn.ba
Luganskogo 54 Street
050051 Almaty
t: +7 7272 62 14 71
jadran@jgl.ru
JGL Split
JGL Macedonia
JGL USA
Varaždinska 51
21000 Split
t: +385 21 542 580
jgl@jgl.hr
Industrijska zona Vizbegovo
10000 Skopje
t: +389 2 26 56 305
borisb@on.net.mk
LLC 310 West 79th Street
10024 New York
t: +1 646 524 7777
grigor.licul@jgl.hr